 Shares of Altimmune Inc. ALT, -0.39 tumbled 44.4 in premarket trading on Wednesday after the company shared new data from an early-stage clinical trial for its experimental treatment for non-alcoholic fatty liver disease that failed to impress investors. The Phase 1b study met both the primary and secondary endpoints of reduction in liver fat content and weight loss, respectively. 